Back to search
Persistent Epithelial Defect
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Persistent Epithelial Defect trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Persistent Epithelial Defect trials you may qualify forPersistent epithelial defects (PED) are corneal ulcers that do not heal within the first two weeks of treatment with artificial tears or ocular lubricant ointme…
After an initial period of standard treatment, they received further care aimed at helping the surface of the eye heal. Clear instructions were given on how to…
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional fu…
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatment…
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED…
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of…
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagn…